JAN 03, 2018 08:14 AM PST

Cancer Immunotherapy: Novel Innate Approaches

Immunotherapy for cancer treatment has been a major are of focus for the past several years, and it has proven effective in multiple cancer types.  Numerous studies are now looking at immunotherapies in combination with other traditional chemotherapy regimens, with personalized medicines, and with inhibitors of epigenetic modifiers.  All of this is great, and contributing to significant strides in the right direction for cancer research.  There are more than 1,000 combination trials harnessing the ability of the immune system to recognize and kill cancer cells, primarily through the use of checkpoint inhibitors or T-cell modification and expansion.  More recently, new evidence has been growing to show that there is another side to the immune system we can harness for therapeutic benefit.

While the current approach deals with the adaptive immune response where immune cells surveil their environment and react in response to certain antigen after identification and processing to arm an “attack” on the antigen’s host, there are new reports that the innate immune response, which is far less complex and more immediate, may also elicit a therapeutically beneficial response.  Major companies such as Merck, Novartis, and Bristol Myers Squibb have been investing in this approach with so far, good results.  The idea here is that so-called “cold” tumors, or those that are uninflamed and are not eliciting immune response at all, can be “heated” up.  The new innate immune response drug candidates are being investigated to work in combination with the current adaptive immune response therapeutics – so these new candidates are administered to initiate an immune response in an otherwise response-free tumor, and then once the immune cells have infiltrated the tumor, the adaptive response drugs can act to optimize the overall immune response waged on the tumor. 

These drugs which are aimed to elicit immune response are also being studied for other conditions aside from cancer, such as autoimmune diseases.  In cancer, they have already made it into Phase I clinical trials.  This new approach is very exciting and promising, and is making waves in the cancer research community.

Sources: Nature Reviews Drug Discovery, Wikipedia, Pixabay, Youtube, Aladdin Creations

 

About the Author
You May Also Like
DEC 05, 2018
Cancer
DEC 05, 2018
Zika virus as a weapon against brain cancer
Glioblastoma is the most aggressive type of Brain Cancer with an average survival rate of less than two years with treatment. So what if there could be a cure for this type of cancer....
DEC 05, 2018
Videos
DEC 05, 2018
Male Contraceptive Gel is in Clinical Trials
Researchers have started a clinical trial involving 420 participants to test the efficacy of a male contraceptive gel....
DEC 15, 2018
Drug Discovery
DEC 15, 2018
Ebola-Fighting Protein Paves The Way For New Drugs
In a study published in Cell, research at Northwestern University School of Medicine has involved scientists discovering a human protein that could be...
DEC 23, 2018
Drug Discovery
DEC 23, 2018
Super-Drug for Pediatric Leukemia?
In a final study published in Genes & Development, researchers at Northwestern University School of Medicine concluded their discoveries on two success...
JAN 24, 2019
Drug Discovery
JAN 24, 2019
Drug Slows Cancer's Circadian Clock
According to a study done on human kidney cancer cells and acute myeloid leukemia cells in mice, a compound was examined to halt the cancerous growth by st...
FEB 27, 2019
Immunology
FEB 27, 2019
Anti-Inflammatory Meds without Side Effects, Please
Drugs such as ibuprofen or aspirin that relieve pain and lower fever are among the most frequently used drugs worldwide....
Loading Comments...